40-year incidence trends for oropharyngeal squamous cell carcinoma in the United States

Osazuwa‐Peters, Nosayaba; Antisdel, Jastin L.; Varvares, Mark A.

doi:10.1016/j.oraloncology.2017.09.015

Cited by 57 publications

(64 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, D’Souza et al recently found that the percentage of p16‐positive HPV oropharyngeal HNC cases had risen among black individuals . Osazuwa‐Peters et al described a 2.53% decrease in the incidence of oropharyngeal HNC among black males from 1987 to 2014, with the incidence among white males surpassing that of blacks in 2008. However, none of these studies reported information based on an early or late stage disease presentation.…”

Section: Discussionmentioning

confidence: 99%

“…Of all primary tumor sites, the oropharynx was the most likely site for a diagnosis of late-stage disease. The incidence of oropharyngeal cancer has increased dramatically in the United States within the last 40 years, and is predominantly experienced by white individuals, especially white males, 5,6 and in at least the past decade, incidence rates of regional stage oropharyngeal HNC have increased substantially. 4,6,18 This might explain why we found an increasing incidence in the current study.…”

Section: Discussionmentioning

confidence: 99%

“…3 Therefore, it is critical to understand trends in late-stage HNC presentation as well associated risk factors. However, although several studies have described the incidence of HNC in general, or specific HNC anatomic subsites, [4][5][6][7][8] to the best of our knowledge there is a paucity of data focused specifically on late-stage HNC incidence trends. In addition to the American Cancer Society and the Surveillance, Epidemiology, and End Results (SEER) program, 1 to our knowledge very few studies to date have examined incidence trends specifically for late-stage HNC while controlling for key sociodemographic variables such as race and sex.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Rising incidence of late‐stage head and neck cancer in the United States

Thompson‐Harvey

Yetukuri

Hansen

et al. 2019

Cancer

Self Cite

View full text Add to dashboard Cite

Background The current study was conducted to determine whether the incidence of late‐stage head and neck cancer (HNC) is decreasing and to estimate the risk of late‐stage HNC diagnosis based on race and sex. Methods Age‐adjusted incidence rates for patients aged ≥18 years with stage IV HNC were abstracted from the Surveillance, Epidemiology, and End Results database (2004‐2015). Rates were stratified by race, sex, and age. Joinpoint regression estimated annual percent changes (APCs) in rates over time, and logistic regression estimated adjusted odds ratios (aORs). Results There were 57,118 patients with stage IV HNC in the current study cohort, with an average age of 61.9 years. From 2004 to 2015, the age‐adjusted incidence rates for stage IV HNC significantly increased by 26.1% (6.11 per 100,000 person‐years in 2004 to 7.70 per 100,000 person‐years in 2015). White and Asian/Pacific Islander/American Indian/Alaska Native patients had significant increases in incidence (APC for white patients, 3.03 [P < .01] and APC for other races, 1.95 [P < .01]), whereas rates among black patients remained stable but were highest across racial groups. Incidence was higher among males compared with females. When restricted only to patients with stage IVC (metastatic) HNC, there remained a significant increase in incidence, especially for oropharyngeal cancer, which showed a 22.9% increase (0.21 per 100,000 person‐years in 2004 vs 0.25 per 100,000 person‐years in 2015). Despite a decreasing overall incidence of stage IV HNC in black patients (aOR, 1.28; 95% CI, 1.22‐1.34) they, along with males (aOR, 3.95; 95% CI, 3.80‐4.11), had significantly increased risks of being diagnosed with late‐stage HNC. Conclusions There is an increasing incidence of late‐stage HNC in the United States, with male patients and black individuals faring the worst.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Rising incidence of late‐stage head and neck cancer in the United States

Thompson‐Harvey

Yetukuri

Hansen

et al. 2019

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…A limitation of this study is the lack of information about HPV status in SEER. We therefore used anatomical sites that are well established for HPV‐related OSCC . Because only 72% to 75% of cancers of these sites are HPV positive, this could lead to overestimation of SPM risk among patients with index potentially HPV‐related HNSCC.…”

Section: Discussionmentioning

confidence: 99%

“…The main exposure was HPV‐relatedness, based on whether patients’ index HNSCC was potentially HPV‐related or HPV‐unrelated. Because the SEER database does not record HPV status for patients, patients with a first potentially HPV‐related HNSCC were defined according to Chaturvedi et al based on ICD‐O‐3 topography: oropharynx (C100–109), tonsil (lingual and palatine, C024 and C090–099, respectively), base of tongue (C019), and Waldeyer ring (C142). About 72% to 75% of all tumors found in the sites described by Chaturvedi (oropharynx, base of tongue, lingual and palatine tonsil, and Waldeyer ring) are HPV positive .…”

Section: Methodsmentioning

confidence: 99%

Risk and outcomes for second primary human papillomavirus–related and –unrelated head and neck malignancy

et al. 2018

Self Cite

View full text Add to dashboard Cite

Objectives/Hypothesis To 1) examine the characteristics of patients who develop second primary malignancies (SPMs) from an index human papillomavirus (HPV)‐related head and neck squamous cell carcinoma (HNSCC) and HPV‐unrelated HNSCC and to 2) compare overall survival between those with HPV‐related and HPV‐unrelated index HNSCC among patients who develop SPM. Study Design Retrospective cohort analysis. Methods A retrospective study was conducted of 113,259 patients who were diagnosed with HNSCC from 2000 to 2014. SPM was defined as the first subsequent primary cancer occurring at least 2 months after index cancer diagnosis, and HPV‐relatedness was based on whether patients’ index HNSCC was potentially HPV‐related or HPV‐unrelated. Multivariable Fine and Gray (FG) competing‐risks regression models were used to estimate factors associated with risk of SPM by HPV‐relatedness. Among patients with SPM, an adjusted Cox proportional hazards (PH) regression model was used to assess the association between HPV‐relatedness and survival. Results Approximately 13,900 patients (12.3%) developed SPM. In the FG model, patients with HPV‐unrelated HNSCC had a 15% higher risk of developing SPM (adjusted hazard ratio: 1.15, 95% confidence interval: 1.10‐1.20) than those with potentially HPV‐related HNSCC, but the same characteristics were associated with SPM development. In the Cox PH model, patients with SPM whose index HNSCC was HPV‐unrelated had higher risk of death than those whose index HNSCC was potentially HPV‐related (adjusted hazard ratio: 1.06; 95% confidence interval: 1.02‐1.11). Conclusions Patients with HPV‐unrelated HNSCC have a higher risk of SPM development than do those with HPV‐related HNSCC. Effective secondary disease‐prevention strategies should be established to improve long‐term patient outcomes. Level of Evidence NA Laryngoscope, 129:1828–1835, 2019

show abstract